临床试验研究设计终点和生物标志物药物安全性

关键字：类型：

下载页码(大于等于0,小于611)：

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

临床试验研究设计终点和生物标志物药物安全性 890条(本栏目收费,不能显示细节,电话13136136841)

Charter Board Meetings and Reports,464–465 464 465

Board Membership,463 463

Communications,467 467

Conflict of Interest,464 464

DMC Recommendations,466–467 466 467

Introduction,463 463

Participants,465 465

Periodic Reports,466 466

Review Materials,465 465

Role of the Board,463 463

Sponsor’s Decisions and Announcements,468 468

Stopping Rules,467 467

Term,463 463

Timetable,468 468

Unscheduled Meetings,466 466

overview,441,460–462 441 460 462

Data manager functions,441–442 441 442

Dear Healthcare Professional letter acne medications,456–457 456 457

appetite suppressants,457 457

birth control pills,455–456 455 456

example,454–455 454 455

overview,452–454 452 454

run-in period and baseline adverse event detection,52 52

serious adverse event,424 424

unexpected adverse drug reaction,425 425

Advisory Committee meetings,600 600

ALL see Acute lymphocytic leukemia Allin study,347 347

Allocation concealment blinding comparison,112–113 112 113

importance,113–114 113 114

enrollment over time,122–123 122 123

最新招商产品更多>>

浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　

浙公网安备:330683240604819103159
　医药代理商群１：

医药代理商群２：

医药代理商群３：